74 related articles for article (PubMed ID: 25047940)
1. Synthesis and biological evaluation of pyrido[2,3-d]pyrimidine-2,4-dione derivatives as eEF-2K inhibitors.
Edupuganti R; Wang Q; Tavares CD; Chitjian CA; Bachman JL; Ren P; Anslyn EV; Dalby KN
Bioorg Med Chem; 2014 Sep; 22(17):4910-6. PubMed ID: 25047940
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy.
Guan Y; Jiang S; Ye W; Ren X; Wang X; Zhang Y; Yin M; Wang K; Tao Y; Yang J; Cao D; Cheng Y
Cell Death Dis; 2020 Nov; 11(11):948. PubMed ID: 33144562
[TBL] [Abstract][Full Text] [Related]
3. ADP enhances the allosteric activation of eukaryotic elongation factor 2 kinase by calmodulin.
Piserchio A; Long KJ; Browning LS; Bohanon AL; Isiorho EA; Dalby KN; Ghose R
Proc Natl Acad Sci U S A; 2023 Apr; 120(17):e2300902120. PubMed ID: 37068230
[TBL] [Abstract][Full Text] [Related]
4. Solution Structure of the Carboxy-Terminal Tandem Repeat Domain of Eukaryotic Elongation Factor 2 Kinase and Its Role in Substrate Recognition.
Piserchio A; Will N; Giles DH; Hajredini F; Dalby KN; Ghose R
J Mol Biol; 2019 Jul; 431(15):2700-2717. PubMed ID: 31108082
[TBL] [Abstract][Full Text] [Related]
5. Revealing eEF-2 kinase: recent structural insights into function.
Piserchio A; Dalby KN; Ghose R
Trends Biochem Sci; 2024 Feb; 49(2):169-182. PubMed ID: 38103971
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, Herbicidal Activity, Mode of Action, and In Silico Analysis of Novel Pyrido[2,3-
Min L; Liang W; Bajsa-Hirschel J; Ye P; Wang Q; Sun X; Cantrell CL; Han L; Sun N; Duke SO; Liu X
Molecules; 2023 Oct; 28(21):. PubMed ID: 37959782
[TBL] [Abstract][Full Text] [Related]
7. Discovery and development of a small molecule library with lumazine synthase inhibitory activity.
Talukdar A; Breen M; Bacher A; Illarionov B; Fischer M; Georg G; Ye QZ; Cushman M
J Org Chem; 2009 Aug; 74(15):5123-34. PubMed ID: 19552377
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of pyrido[3,2-d]pyrimidine derivatives as novel ATR inhibitors.
Duan Y; Zhuang L; Xu Y; Cheng H; Xia J; Lu T; Chen Y
Bioorg Chem; 2023 Jul; 136():106535. PubMed ID: 37086581
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, anticancer activity and molecular docking of new quinolines, quinazolines and 1,2,4-triazoles with pyrido[2,3-
Abu-Hashem AA; Hakami O; Amri N
Heliyon; 2024 Mar; 10(5):e26735. PubMed ID: 38468950
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of novel bioactive pyrido[2,3-
Tantawy ES; Nafie MS; Morsy HA; El-Sayed HA; Moustafa AH; Mohammed SM
RSC Adv; 2024 Apr; 14(16):11098-11111. PubMed ID: 38586446
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and cytotoxicity evaluation of novel pyrido[3,4-
Wei L; Malhotra SV
Medchemcomm; 2012 Oct; 3(10):1250-1257. PubMed ID: 25429348
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of pyrido[2,3-d]pyrimidin-7(8H)-one derivatives as potent USP1 inhibitors.
Li H; Liu BJ; Xu J; Song SS; Ba R; Zhang J; Huan XJ; Wang D; Miao ZH; Liu T; He JX; Xiong B
Eur J Med Chem; 2024 Jun; 275():116568. PubMed ID: 38889606
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a new pyrido[2,3-
Rosa FA; Gonçalves DS; Pianoski KE; da Silva MJV; Ames FQ; Aguiar RP; Volpato H; Lazarin-Bidóia D; Nakamura CV; Bersani-Amado CA
RSC Med Chem; 2024 Mar; 15(3):1038-1045. PubMed ID: 38516591
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and cyclometalation of a pyrido[3,2-e]-2,10b-diaza-cyclopenta[c]fluorene-1,3-dione scaffold.
Mulcahy SP; Carroll PJ; Meggers E
Tetrahedron Lett; 2006 Dec; 47(50):8877-8880. PubMed ID: 18071577
[TBL] [Abstract][Full Text] [Related]
15. Using docking and alchemical free energy approach to determine the binding mechanism of eEF2K inhibitors and prioritizing the compound synthesis.
Wang Q; Edupuganti R; Tavares CD; Dalby KN; Ren P
Front Mol Biosci; 2015; 2():9. PubMed ID: 25988177
[TBL] [Abstract][Full Text] [Related]
16. Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine.
Warthaka M; Adelmann CH; Kaoud TS; Edupuganti R; Yan C; Johnson WH; Ferguson S; Tavares CD; Pence LJ; Anslyn EV; Ren P; Tsai KY; Dalby KN
ACS Med Chem Lett; 2015 Jan; 6(1):47-52. PubMed ID: 25589929
[TBL] [Abstract][Full Text] [Related]
17. Reversible covalent inhibition of eEF-2K by carbonitriles.
Devkota AK; Edupuganti R; Yan C; Shi Y; Jose J; Wang Q; Kaoud TS; Cho EJ; Ren P; Dalby KN
Chembiochem; 2014 Nov; 15(16):2435-42. PubMed ID: 25224652
[TBL] [Abstract][Full Text] [Related]
18. Structure of the complex between calmodulin and a functional construct of eukaryotic elongation factor 2 kinase bound to an ATP-competitive inhibitor.
Piserchio A; Isiorho EA; Dalby KN; Ghose R
J Biol Chem; 2023 Jun; 299(6):104813. PubMed ID: 37172726
[TBL] [Abstract][Full Text] [Related]
19. Novel etodolac derivatives as eukaryotic elongation factor 2 kinase (eEF2K) inhibitors for targeted cancer therapy.
Comert Onder F; Siyah P; Durdagi S; Ay M; Ozpolat B
RSC Med Chem; 2022 Jul; 13(7):840-849. PubMed ID: 35923718
[TBL] [Abstract][Full Text] [Related]
20. Irreversible Antagonists for the Adenosine A
Temirak A; Schlegel JG; Voss JH; Vaaßen VJ; Vielmuth C; Claff T; Müller CE
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
